Danieli Maria, Fumagalli Romario Uberto, Radice Davide, Pozzi Simonetta, Spada Francesca, Funicelli Luigi, Fazio Nicola, Bertani Emilio
University of Milan, Milan, Italy.
Division of Digestive Surgery, IEO, European Institute of Oncology IRCCS, Milan, Italy.
Ann Surg Oncol. 2025 Mar;32(3):2141-2149. doi: 10.1245/s10434-024-16588-9. Epub 2024 Dec 3.
The role of prophylactic primary tumor resection (PTR) in patients with small intestinal neuroendocrine tumors (SI-NETs) and unresectable liver metastases is a matter of debate.
We aimed to evaluate outcomes in patients with SI-NETs who underwent PTR, according to the presence of metastasis and symptoms from primary.
Data from patients who underwent PTR for SI-NETs from a single referral center (2007-2023) were prospectively collected. Patients were divided into three groups: non-metastatic (M0) and metastatic with primary tumor-related symptoms (MS) or metastatic asymptomatic (MA). Kaplan-Meier curves for overall survival (OS) and event-free survival (EFS) were generated and compared by group. Univariate and multivariable Cox regression analyses were performed to assess the significance of risk factors.
Of 147 patients, 53 were M0, 23 were MS, and 71 were MA. Median follow-up was 26 months. The 5- and 10-year OS estimates were 100% and 100% in M0 patients, 82 and 21% in MS patients, and 89 and 80% in MA patients, respectively (p < 0.001). Median EFS was 91 months overall and 43,126 months and not reached for the MS, MA, and M0 groups, respectively (p < 0.001). In multivariable analysis, MS (hazard ratio [HR] 3.92, 95% confidence interval [CI] 1.71-9.52), functioning tumors (HR 1.98, 95% CI 1.03-3.81), and G2 grade (HR 3.20, 95% CI 1.64-6.85) were associated with a shorter EFS.
In this large retrospective series, the MS group had a significantly worse OS and EFS compared with M0 and MA. This finding suggests that prophylactic PTR might benefit SI-NET patients with unresectable liver metastases, as symptom development could impair long-term prognosis after surgery.
预防性原发性肿瘤切除术(PTR)在小肠神经内分泌肿瘤(SI-NETs)合并不可切除肝转移患者中的作用存在争议。
我们旨在根据转移情况和原发灶症状,评估接受PTR的SI-NETs患者的预后。
前瞻性收集来自单一转诊中心(2007 - 2023年)接受PTR治疗的SI-NETs患者的数据。患者分为三组:无转移(M0)、有原发肿瘤相关症状的转移患者(MS)或无症状转移患者(MA)。生成总生存(OS)和无事件生存(EFS)的Kaplan-Meier曲线,并按组进行比较。进行单因素和多因素Cox回归分析以评估危险因素的显著性。
147例患者中,53例为M0,23例为MS,71例为MA。中位随访时间为26个月。M0患者的5年和10年OS估计分别为100%和100%,MS患者分别为82%和21%,MA患者分别为89%和80%(p < 0.001)。总体中位EFS为91个月,MS、MA和M0组分别为43、126个月和未达到(p < 0.001)。在多因素分析中,MS(风险比[HR] 3.92,95%置信区间[CI] 1.71 - 9.52)、功能性肿瘤(HR 1.98,95% CI 1.03 - 3.81)和G2级(HR 3.20,95% CI 1.64 - 6.85)与较短的EFS相关。
在这个大型回顾性系列研究中,与M0和MA相比,MS组的OS和EFS明显更差。这一发现表明,预防性PTR可能使合并不可切除肝转移的SI-NETs患者受益,因为症状的出现可能会损害手术后的长期预后。